SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

J.B. Chemicals & Pharmaceuticals gets approval to sell its over-the-counter biz

24 May 2011 Evaluate

J.B. Chemicals & Pharmaceuticals (JBCPL) has received its board’s approval for entering into a definitive agreement to sell its Russia/CIS OTC Business to Cilag GmbH International, a wholly owned subsidiary of Johnson & Johnson. The consideration for this transaction is Rs 9,385.10 million.

Further, the board has also approved the sale of worldwide rights and registrations of 3 OTC brands (Doktor Mom, Rinza and Fitovit) to Cilag, for an additional consideration of Rs 60.67 million. The Russia/CIS OTC Business is being sold as a going concern on a slump sale basis including OTC trademarks, brands, patents, registrations and domain names. The sale will also involve the transfer of the employees of the Russia/ CIS OTC Business.

Cilag‘s affiliate, Johnson & Johnson LLC, has also entered into a contract with the company’s wholly owned subsidiary situated in Russia for purchase of its OTC inventory and receivables for a consideration of $47 million. In addition, the company has signed a long term agreement to supply Cilag finished products for the acquired Russia/CIS OTC Business. The transaction is expected to close in mid 2011.

JBCPL is one of India’s leading pharmaceutical companies which manufacture and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs.

JB Chem & Pharma Share Price

1997.35 22.65 (1.15%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×